<DOC>
	<DOCNO>NCT02547116</DOCNO>
	<brief_summary>Methicillin-susceptible ( MSSA ) Methicillin-resistant ( MRSA ) Staphylococcus aureus ( SA ) two important infectious pathogen CF , 69 % CF patient lung infection MSSA MRSA last year . Wolter co-worker recently demonstrate specific morphologic subtype MSSA MRSA , small-colony variant Staph aureus ( SCV-SA ) , associate great decline lung function bad clinical outcome . SCV-SA already recognize ability contribute persistent infection , likely due SCV-SA 's ability intracellular growth , well increase antibiotic resistance compare normal-colony SA . To investigate epidemiology clinical significance SCV-SA CF , explore hypothesis SCV-SA may require unique antibiotic treatment strategy optimize clinical response , investigator perform follow : 1 . Characterize epidemiology SCV-SA infection adult pediatric CF population investigate clinical significance SCV-SA infection CF compare clinical characteristic outcome CF patient SCV-SA compare normal-colony MSSA/MRSA . 2 . Characterize unique microbiologic characteristic SCV-SA infection CF evaluate antibiotic susceptibility profile molecular characteristic SCV-SA two large CF patient population . 3 . Perform 16-patient pilot study novel treatment SCV-SA infection CF , utilize low dose rifampin combination standard anti-SA antibiotic . These investigation delineate role SCV-SA pathogen CF provide guidance optimize treatment strategy MSSA/MRSA CF lung infection .</brief_summary>
	<brief_title>Epidemiology Treatment Small-colony Variant Staphylococcus Aureus Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>1 . Male female ≥ 12 year age 2 . Confirmed diagnosis CF base follow criterion : positive sweat chloride &gt; 60 mEq/liter ( pilocarpine iontophoresis ) and/or genotype two identifiable mutation consistent CF abnormal NPD , one clinical feature consistent CF phenotype . 3 . Written informed consent ( assent applicable ) obtain subject subject 's legal representative ability subject comply requirement study . 4 . Two positive SCVSA respiratory culture last two year least six month apart , plus positive SCVSA respiratory culture Screening Visit Runin ( Day 14 ) Visit . 5 . FEV1 &gt; 30 % predict normal age , gender , height Screening . 6 . Weight &gt; 35 kg 7 . Females childbearing potential must agree practice one highly effective method birth control , include abstinence . Note : highly effective method birth control , alone combination , result failure rate le 1 % per year use consistently correctly . Female patient utilize hormonal contraceptive birth control method must use method least 3 month study dose . If patient use hormonal form contraception , patient require also use barrier contraceptive rifampin affect reliability hormone therapy . Barrier contraceptives male condom diaphragm acceptable use combination spermicide . 1 . An acute upper low respiratory infection , pulmonary exacerbation , change routine therapy ( include antibiotic ) pulmonary disease within 14 day screen visit . 2 . Use oral inhale antiMRSA drug within two week Screening Visit . 3 . History intolerance rifampin TMP/SMX , minocycline , doxycycline . 4 . Resistance rifampin TMP/SMX , minocycline doxycycline screening . 5 . Abnormal renal function , define creatinine clearance &lt; 50 mL/min use CockcroftGault equation adult Schwartz equation child , Screening . 6 . Abnormal liver function , define ≥3x upper limit normal ( ULN ) , serum aspartate transaminase ( AST ) serum alanine transaminase ( ALT ) , know cirrhosis . time Screening . 7 . Serum hematology chemistry result judgment investigator would interfere completion study . 8 . History list solid organ hematological transplantation 9 . History sputum culture nontuberculous Mycobacteria last 6 month . 10 . History sputum culture Burkholderia Cepacia last year . 11 . Planned continuous use soft contact lenses take rifampin access glass . 12 . Taking voriconazole unable discontinue use enrol study . 13 . Administration investigational drug device within 28 day screen within 6 halflives investigational drug ( whichever longer ) 14 . Female patient childbearing potential pregnant lactating , plan become pregnant 15 . Any serious active medical psychiatric illness , opinion investigator , would interfere patient treatment , assessment , adherence protocol . 16 . Patients take certain drug exclude study : . Drugs , contraindicate rifampin use ( addition voriconazole ) : i. Antiretrovirals : fosamprenavir , atazanavir , lopinavir , saquinavir , nelfinavir , tipranavir , darunavir , rilpivirine , telaprevir , boceprevir , elvitegravir , maraviroc ii . Drugs use increase systemic exposure antiretrovirals : Cobicistat iii . Anthelmintic/Antimalarial agent : praziquantel , artemether iv . Antianginal agent : ranolazine v. Psychiatric medication : lurasidone b . Other drug , contraindicate , listed major drug drug interaction i. Antiretrovirals : ritonavir , indinavir , efavirenz , nevirapine , etavirine</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>